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a b s t r a c t
Gonadotrophin-releasing hormone (GnRH) acts via seven transmembrane receptors on gonadotrophs to
stimulate gonadotrophin synthesis and secretion, and thereby mediates central control of reproduction.
Type I mammalian GnRHR are unique, in that they lack C-terminal tails. This is thought to underlie
their resistance to rapid homologous desensitisation as well as their slow rate of internalisation and
inability to provoke G-protein-independent (arrestin-mediated) signalling. More recently it has beenonadotrophin-releasing hormone
esensitisation
rafﬁcking
maging
ulsatility
discovered that the vast majority of human GnRHR are actually intracellular, in spite of the fact that they
are activated at the cell surface by a membrane impermeant peptide hormone. This apparently reﬂects
inefﬁcient exit from the endoplasmic reticulum and again, the absence of the C-tail likely contributes to
their intracellular localisation. This review is intended to cover some of these novel aspects of GnRHR
biology, focusing on ways that we have used automated ﬂuorescence microscopy (high content imaging)
to explore GnRHR localisation and trafﬁcking as well as spatial and temporal aspects of GnRH signalling
via the Ca2+/calmodulin/calcineurin/NFAT and Raf/MEK/ERK pathways.
© 2010 Elsevier Ireland Ltd. 
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. Introduction
GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, also
nown as GnRH I) stimulates secretion of luteinising hormone (LH)
nd follicle-stimulating hormone (FSH) from gonadotrophs, and
It also activates protein kinase C (PKC) isozymes and mitogen-
activated protein kinase (MAPK) cascades which (together with
Ca2+/calmodulinand its effectors), control gonadotrophin synthesis
(Stojilkovic and Catt, 1995b; Millar et al., 2004; Cheng and Leung,
2005). Most vertebrates also express the highly conserved GnRH
Open access under CC BY license.hereby mediates central control of reproduction. It acts primarily
ia Gq-coupled seven transmembrane (7TM) receptors to stimu-
ate phospholipase C, with consequent mobilisation of Ca2+, which
ediates acute stimulation of exocytotic gonadotrophin secretion.
∗ Corresponding author.
E-mail address: Craig.McArdle@bristol.ac.uk (C.A. McArdle).
303-7207 © 2010 Elsevier Ireland Ltd. 
oi:10.1016/j.mce.2010.07.008
Open access under CC BY license.II ([His5, Trp7, Tyr8]GnRH I) and ligand selective receptors have
evolved in parallel with these distinct forms of GnRH. Mammalian
type I GnRHR are selective for GnRH I and lack C-terminal tails
(Millar et al., 2004; Cheng and Leung, 2005). This unique struc-
tural feature has major implications for receptor function and also
offers some informative research strategies. In recent years we
have increasingly used imaging readouts for interrogation of GnRH
function. The array of ﬂuorescent labelling reagents now avail-
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ble to researchers allows quantiﬁcation of events in intact ﬁxed
nd live cells in imaging assays, which can readily be expanded
o integrate complex information by using multiple ﬂuorophore
eporters (Pepperkok and Ellenberg, 2006; Lang et al., 2006). The
ecent development of affordable high content microscopy (HCM)
latforms permits automated image acquisition from cells and tis-
ues in multiwell plate formats allowing efﬁcient capture of single
ell information, such as subcellular protein compartmentalisa-
ion (Pepperkok and Ellenberg, 2006; Lang et al., 2006). Stored
mages can then be analysed using pre-deﬁned software algo-
ithms, allowing the whole workﬂow to become unbiased and
utomated. The development of this technology has largely been
riven by the need for improved secondary screening in drug dis-
overy, but the increased throughput and statistical power of these
pproaches has seen their increasing adoption by academic labo-
atories (Pepperkok and Ellenberg, 2006; Lang et al., 2006). This
ovetails with the rapid increase in free bioinformatic data and the
ffordability of large-scale plasmid, small molecule and RNA inter-
erence libraries. In this review we will outline some of the HCM
pproaches we have developed to interrogate GnRHR trafﬁcking
nd signalling.
. Desensitisation and internalisation
For many 7TM receptors, agonist-activated receptor con-
ormations are substrates for G-protein receptor kinases. This
hosphorylation occurs most often within the receptor’s carboxy-
erminal tail (C-tail), and facilitates binding to -arrestins that
ediate receptor desensitisation and internalisation, aswell as sig-
alling to arrestin-scaffolded effectors (Pierce and Lefkowitz, 2001;
uttrell and Lefkowitz, 2002). Agonist-induced phosphorylation,
rrestin binding, arrestin-mediated desensitisation, internalisation
nd signalling have all been shown with non-mammalian GnRHR
e.g. catﬁsh or Xenopus GnRHR, both of which have C-tails with
ultiple potential phosphorylation sites) but not for tailless type
GnRHR (Heding et al., 2000; McArdle et al., 2002; Ronacher et
l., 2004; Hislop et al., 2005; Caunt et al., 2006b). Thus the advent
f type I mammalian GnRHR has been associated with the loss of
unctionally relevant C-tails (Davidson et al., 1994; McArdle et al.,
995, 1996; Heding et al., 1998; Blomenrohr et al., 1999; Willars
t al., 1999; Hislop et al., 2000; Vrecl et al., 2000; Heding et al.,
000; Willars et al., 2001; McArdle et al., 2002; Millar et al., 2004).
ack of type I mammalian GnRHR desensitisation is intriguing in
ight of the fact that sustained stimulation causes desensitisation of
nRH-stimulated gonadotrophin secretion. Moreover, this desen-
itisation underlies the therapeutic use of GnRH agonists in clinical
reatment (Conn et al., 1987; Stojilkovic and Catt, 1995a; McArdle
t al., 2002; Millar et al., 2004; Cheng and Leung, 2005). Desen-
itisation of GnRH-stimulated gonadotrophin secretion must be
ue to down-stream adaptive changes, making type I GnRHR an
xcellent model for exploration of such changes in the absence
f direct receptor desensitisation. For example, we have previ-
usly shown that sustained GnRH treatment caused a pronounced
own-regulation of inositol 1,4,5 trisphosphate (IP3) receptors and
onsequent desensitisation of GnRH effects on the cytoplasmic
a2+ concentration [Ca2+]i (Willars et al., 2001; McArdle et al.,
002). Other mechanisms that may contribute to desensitisation of
nRH effects on [Ca2+]i and/or exocytotic gonadotrophin secretion
nclude GnRH-mediated desensitisation of voltage-operated Ca2+
hannels (Stojilkovic and Catt, 1995a) and agonist-induced GnRHR
nternalisation (below). In the long-term, depriving gonadotrophs
f the pulsatile GnRHneeded for efﬁcient transcription of the genes
ncoding the GnRHR and gonadotropin subunits (below) may con-
ribute to or explain, the chemical castration caused by GnRH
gonists in vivo (Huhtaniemi et al., 2009).r Endocrinology 331 (2011) 194–204 195
3. GnRHR as intracellular proteins
One of the most surprising recent discoveries in this ﬁeld is that
human (h)GnRHR are largely intracellular. This developed from
work on GnRHR point mutations that cause infertility (hypogo-
nadotropic hypogonadism). Although initially thought to perturb
signalling, itwas found thatmostof thesemutationsactually impair
trafﬁcking and reduce the cell surface number of GnRHR (Brothers
et al., 2004).Moreover, amembrane permeant non-peptide GnRHR
antagonist (IN3) could facilitate signalling viamost of thesemutant
hGnRHR (Janovick et al., 2002, 2003; Ulloa-Aguirre et al., 2004;
Brothers et al., 2006; Conn et al., 2006; Conn et al., 2007; Conn
and Janovick, 2009). By analogy with other 7TM receptors (Petaja-
Repo et al., 2000; Edwards et al., 2000; Petaja-Repo et al., 2001;
Tan et al., 2004; Bernier et al., 2004; Dong et al., 2007), this antag-
onist is thought to act as a pharmacological chaperone, enabling
the conformational change in GnRHR required for trafﬁcking from
the endoplasmic reticulum (ER) to the surface. Consistentwith this,
it was found that calnexin, a major component of the cell’s ER exit
quality control system,was able to bind to GnRHR and reduce func-
tional GnRHR expression at the cell surface (Brothers et al., 2006;
Yanez and Conn, 2010). Interestingly, the non-peptide antagonist
also caused a modest increase in signalling via wild-type hGnRHR
suggesting that there is a signiﬁcant reserve of potentially func-
tional wild-type hGnRHR within the cell.
The ability of pharmacological chaperones to increase cell sur-
face hGnRHR expression was initially inferred from increased
GnRH-stimulated [3H]IPx accumulation (Janovick et al., 2002, 2003;
Ulloa-Aguirre et al., 2004; Brothers et al., 2006; Conn et al.,
2006, 2007) and then documented by microscopy. The latter
approach has been hampered by the lack of validated antibod-
ies to normal GnRHR, so we have developed models based on
adenovirus (Ad)-mediated expression of GnRHR with N-terminal
(exofacial) haemagglutinin (HA) epitope tags and indirect immuno-
ﬂuorescence staining coupled with automated image acquisition
and analysis. Using this we simply quantiﬁed HA-GnRHR staining
at the cell surface (anti-HA added to intact cells) and the whole cell
(anti-HA added to permeabilised cells) for a range of GnRHR con-
structs and cell types incubated with or without IN3 (Finch et al.,
2008, 2010). We calculated whole cell and cell surface expression
indices (%positive cells xmeanﬂuorescence intensity in those cells)
and used these to determine the proportional cell surface expres-
sion (PCSE) as shown in Fig. 1. This revealed that a remarkably small
proportion of HA-hGnRHR is located at the cell surface (PCSE <1% in
most cell types tested). In contrast, the PCSE of a non-mammalian
GnRHR (the XGnRHR) was much higher (40–60%) and addition
of the XGnRHR C-tail to the hGnRHR (h.XGnRHR) increased PCSE
approximately 5-fold. Accordingly, the absence of any C-terminal
tail may also contribute to this unusual aspect of hGnRHR func-
tion, althoughother structural features includingaprimate-speciﬁc
Lys191 (Ulloa-Aguirre et al., 2004; Conn et al., 2007) and a second
extracellular glycosylation site (Davidson et al., 1995) are undoubt-
edly also involved.
The low proportion of HA-hGnRHR at the cell surface (<1% in
MCF7 cells) is remarkable in light of the robust hGnRHR-mediated
[3H]IPx accumulation seen in these cells (Finch et al., 2004, 2008).
This led us to suspect that the HA-tag was inﬂuencing receptor
function (Brothers et al., 2003) but we have found no effect of the
tag on binding afﬁnity or speciﬁcity in binding assays or on lig-
and potency and speciﬁcity in functional assays (Finch et al., 2008,
2010).Wewerealso concerned that the imagingassay simplyquan-
tiﬁes the proportion of HA tag at the cell surface and that thismight
not equate to functional GnRHR but we have found effects of IN3
on receptor expression are paralleled by effects on receptor func-
tion in a number of assays. These include GnRHR-mediated [3H]IP
accumulation assays (Finch et al., 2008) and GnRHR-mediated
196 S.P. Armstrong et al. / Molecular and Cellular Endocrinology 331 (2011) 194–204
Fig. 1. An automated imaging assay for GnRHR quantiﬁcation. Cells grown in 96 wells were transduced with Ad expressing N-terminal HA-tagged hGnRHR, XGnRHR or
h.XGnRHR then incubated ∼20h with 0 or 1M of the non-peptide antagonist IN3 before indirect ﬂuorescence labelling of cell surface receptors (primary antibody added
to intact cells) or whole cell receptors (primary antibody added after permeabilisation). Nuclei were also stained with DAPI and digital images were captured using a 10×
objective and a 0.6mm2 ﬁeld of view. Panel A shows representative images (each approximately 25% of the ﬁeld captured) of whole cells and cell surface staining in cells
transduced with the indicated receptors. Panel B shows a higher power image of nuclei, HA-XGnRHR and merged stains from the boxed region in panel A. It also illustrates
the automated image segmentation used to deﬁne perimeters of nuclei (blue) and cells (green or red) and application of a ﬁlter to distinguish cells in which staining was
>10% above background (green perimeters) or <10% above background (red perimeters). Receptors can be quantiﬁed by calculation of an expression index (EI =% +ve stained
cells×mean ﬂuorescence intensity in those cells) and proportional cell surface expression (PCSE) is calculated as the cell surface EI as a % of the whole cell EI. Panel C shows
PCSE values calculated from the same representative experiment as used for panels A and B. Panel D shows the cell surface EI for HA-hGnRHR in control and IN3 pre-treated
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dapted from Finch et al. (2009).
FAT2-EFP (nuclear factor of activated T cells-emerald ﬂuorescent
rotein) translocation assays (Finch et al., 2009) as well as antipro-
iferative and pro-apoptotic effects of GnRHR activation in MCF7
ells (Finch et al., 2008). In each case, IN3 behaves as a competitive
nRHR antagonist, but when long-term co-incubation protocols
re used the IN3 increases cell surface hGnRHR expression and
an actually increase GnRH effects. These functional data parallel
he imaging, supporting the notion that the majority of hGnRHR
re located in a potentially functional intracellular pool that can
e brought to the cell surface by pharmacological chaperones.
ogether, the co-localisation studies and effects of pharmacological
r biochemical chaperones suggest that these intracellular hGnRHR
re primarily within the ER (Brothers et al., 2004, 2006; Sedgley
t al., 2006) although there are presumably also hGnRHR within
etrograde and/or anterograde transport vesicles and early studies
uggested their presence in the nucleus or nuclear envelope (Millar
t al., 1983; Halmos and Schally, 2002) as recently demonstrated
or epitope-tagged GnRHR (Re et al., 2010).
. Agonist-induced GnRHR down-regulation and trafﬁckingThe discovery that hGnRHR are largely intracellular also has
mportant implications for understanding trafﬁcking from the cell
urface. It is often assumed that agonist-induced internalisation
nd down-regulation contributes to the efﬁcacy of GnRH agonistsed reduction in cell surface hGnRHR expression is only evident in IN3 pre-treated
in cancer therapy but there is very little direct evidence for such
regulation of hGnRHR. Extrapolation from the early studies per-
formed primarily with rodent GnRHR (Schvartz and Hazum, 1987;
Lin et al., 1998; Petaja-Repo et al., 2000; Pierce et al., 2002) is less
compelling in light of the known differences between rodent and
hGnRHR compartmentalization (and hence trafﬁcking (McArdle et
al., 1995, 2002)), and a recent study (monitoring uptake of radio-
labelled antibodies targeting tagged GnRHRs) revealed that type I
mammalian GnRHR undergo constitutive but not agonist-induced
internalisation in COS-7 orHEK293 cells (Pawson et al., 2008).With
this in mind we adapted our automated imaging methods to moni-
tor cell surface expression and trafﬁcking of HA-tagged GnRHR. We
found that GnRH II rapidly reduces cell surface XGnRHR expres-
sion, and that GnRH reduces cell surface mouse (m)GnRHR and
h.XGnRHR but saw no effect of GnRH on cell surface hGnRHR,
which is not surprising given the low cell surface expression of this
receptor in unstimulated cells (Fig. 1). However, when cells were
pre-treated with IN3 to increase cell surface receptor expression,
subsequent GnRH addition did cause a pronounced reduction in
cell surface hGnRHR, h.XGnRHR and mGnRHR (Fig. 1 and (Finch et
al., 2009, 2010)). This down-regulation of cell surface hGnRHR was
dependent upon signalling because no such effect was seen in cells
expressing a mutant of the hGnRHR (A261K) that does not activate
its cognate G-protein (Myburgh et al., 1998), and was also reversed
by addition of cetrorelix 2h after the agonist (Finch et al., 2009,
S.P. Armstrong et al. / Molecular and Cellular Endocrinology 331 (2011) 194–204 197
Fig. 2. Peptide and non-peptide antagonist effects on GnRHR localisation. Panels A–C: HeLa cells transduced with Ad HA-hGnRHR, h.XGnRHR or A261K-hGnRHR were
incubated ∼20h in medium with the indicated concentration of IN3 with 0 (ctrl.) or 10−7 M cetrorelix (cet.) before determining the cell surface expression index, as above.
Note that cetrorelix had no effect onHA-hGnRHR alone, but synergisedwith IN3 to increase cell surface expression of hGnRHR. Similar effectswere seen in cells expressing the
signalling-deﬁcient A261KhGnRHRmutant, demonstrating that the IN3 and cetrorelix effects on cell surface hGnRHRexpression are not dependent uponG-protein activation.
Panel D: cells transduced with Ad HA-h.XGnRHR or hGnRHR were incubated for 60min with anti-HA at 21 ◦C. They were then washed and incubated for 60min with 10−7 M
GnRH or cetrorelix, or without test compound (ctrl.) before ﬁxation and staining (DAPI and anti-HA). In HA-h.XGnRHR expressing cells GnRH caused an increase in bright
p o endo
( ls bec
l in inc
e by slo
A
2
m
(
a
a
o
w
h
t
m
e
r
i
d
t
(
w
c
N
m
s
c
iunctate anti-HA staining (indicating agonist-induced receptor internalisation int
panel E). Note that inclusions were not measurable in HA-hGnRHR expressing cel
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ffect. The implication is that the peptide increases cell surface hGnRHR expression
dapted from Finch et al. (2009).
010). We also used antibody loading and automated imaging to
onitor receptor trafﬁcking to punctate regions within the cells
presumably endosomes). These “granularity assays” revealed that
gonists stimulate the trafﬁcking of hGnRHR, h.XGnRHR, mGnRHR
nd XGnRHR (but not A261K-h.XGnRHR) and the internalisation
f h.XGnRHR. Using ﬂuorescent transferrin to label endosomes,
e found that agonists stimulate redistribution of hGnRHR and
.XGnRHR to punctuate regions where they are co-localised with
ransferrin. Similar data have been previously seen by confocal
icroscopy (i.e. for HA-tagged rat GnRHR in HEK293 cells, (Vrecl
t al., 2000)) supporting the notion that GnRH also stimulates the
edistribution of HA-GnRHR from the cell surface to endosomes
n the HeLa cell model. However, our internalisation assay was
ependentupon loadingof anti-HA tocell surfaceHA-GnRHRat low
emperature and labelling was too low for imaging of the hGnRHR
because cell surface receptor expression was low). Consequently,
e could demonstrate agonist-induced hGnRHR trafﬁcking but
ould not test for agonist-induced hGnRHR internalisation (Fig. 2).
evertheless, the parallel effects of agonist on cell surface hGnRHR,
GnRHR and h.XGnRHR, as well as their trafﬁcking and internali-
ation (where measurable) clearly support the notion that agonists
an reduce cell surface hGnRHR number by stimulating hGnRHR
nternalisation.somes) and this was measured using a granularity assay to quantify “inclusions”
ause there are too few hGnRHR at the cell surface for efﬁcient labelling during the
lusion count in HA-h.XGnRHR expressing cells, whereas cetrorelix had the opposite
wing its internalisation from the cell surface.
5. Ligand biased efﬁcacy
Conventional receptor theoryassumes that thereare single inac-
tiveandactive receptor conformations, and that antagonistsoccupy
the former, whereas agonists induce or stabilise the latter. It is
increasingly recognised, however, that there are multiple active
conformations for many (probably all) 7TM receptors (Galandrin
and Bouvier, 2006; Kenakin, 2007). The overriding reason for inter-
est in multiple active 7TM receptor conformations is that these
distinct conformations may not only be preferentially induced or
stabilised by different ligands but may also couple differentially
to distinct effectors. This provides the basis for “ligand-biased
efﬁcacy” (also known as “ligand-directed trafﬁcking of receptor
signalling”) that has recently been reported for GnRHR. Thus we
found that PKC activation increased afﬁnity of XGnRHR for GnRH
II but not for buserelin, demonstrating the existence of multiple
active GnRHR conformations (Caunt et al., 2004), and different
active conformations of rat and hGnRHR are thought to mediate
antiproliferative effects andGq/11 activation in somemodels (Lopez
de et al., 2008). The effect of non-peptide antagonists on cell sur-
face expression of GnRHR demonstrates the existence of multiple
GnRHR conformations (that do or do not trafﬁc efﬁciently to the
cell surface) within the cell. Although it is not clear how these are
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elated toactive conformationsat thecell surface, recentworkcom-
aring effects of peptide and non-peptide antagonists on GnRHR
xpression is more directly pertinent to this issue. Using the imag-
ng assays above, we found that IN3 increased the number and
roportion of HA-hGnRHR at the cell surface in MCF7 (breast can-
er) cells, and that this effect was not mimicked or blocked by
eptide antagonists (antide and cetrorelix). This is entirely consis-
ent with IN3 acting intracellularly to facilitate hGnRHR trafﬁcking
o the cell surface, and the membrane impermeant peptide antago-
ists being ineffective because they do not access the intracellular
ite of IN3 action. However, we were surprised to ﬁnd that the
eptide antagonists did cause a modest increase in cell surface
xpression of the h.XGnRHR (Finch et al., 2008). We reasoned
hat the peptides might do so by slowing internalisation from the
ell surface and that their effect would therefore only be evident
hen there are appreciable numbers of receptors at the surface.
o address this we performed similar experiments in HeLa cells
PCSE values for hGnRHR and h.XGnRHR are higher in HeLa than
n MCF7 cells) and also tested for possible interaction between
eptide and non-peptide antagonists. We found that antide and
etrorelix have comparable efﬁcacy and greater potency than IN3
t increasing cell surface h.XGnRHR expression in HeLa cells (Finch
t al., 2010). Although these peptides had no measurable effect on
ell surface hGnRHR expression alone, they did synergize with IN3
o increase cell surface hGnRHR expression and did increase mGn-
HR expression ((Finch et al., 2010) and Fig. 2). They also slowed
.XGnRHR internalisation, as measured using the granularity assay
escribed above ((Finch et al., 2010) and Fig. 2) and increased cell
urface expression of hGnRH and mGnRHR in LT2 gonadotroph
ells. Thus it appears that the two types of antagonist have the
otential to increase cell surface GnRHR number in different ways;
he membrane permeant non-peptide antagonist acting within the
ell to accelerate trafﬁcking to the PM, and the membrane imper-
eant peptide acting at the cell surface to slow trafﬁcking from
he PM (Table 1). These data demonstrate an unexpected feature of
he peptide antagonists. In functional assays reporting Gq/11 acti-
ation ([3H]IPx accumulation and NFAT-EFP translocation), GnRH
nd buserelin are full agonists and cetrorelix is thought to be a full
ntagonist (33,34), inﬂuencing receptor function solely by inhibit-
ng agonist effects. In contrast, in the HA-h.XGnRHR internalisation
ssay, GnRH and buserelin are agonists but cetrorelix acts as an
nverse agonist, reducing internalisation in the absence of GnRH.
ost importantly, this data reveals the existence of an antagonist-
ccupied GnRHR conformation at the cell surface that differs from
hat of the unoccupied receptor, and demonstrates the occurrence
f ligand-biased efﬁcacy at GnRHR with therapeutically relevant
igands (cetrorelix and buserelin), normal (i.e. non-tailed) recep-
ors and in gonadotroph lineage cells (Table 1). Such effects may
lso be pertinent to GnRHR signalling in non-pituitary sites (i.e.
able 1
igand effects on GnRHR signalling and trafﬁcking.
High afﬁnity binding Signalling to Gq/11 A
Unliganded GnRHR N/A None S
+GnRH or Buserelin Yes ↑↑ –
+Cetrorelix Yes – –
+IN3 Yes – ↑
he table summarises data obtained by HCM in HeLa, MCF7 and LT2 cell models as des
userelin are pure agonists whereas cetrorelix and IN3 are pure antagonists. The non-pe
GnRHR) to the plasma membrane whereas the membrane impermeant peptides (GnR
nRH and buserelin increase retrograde trafﬁcking (internalisation) of GnRHR whereas c
f cell surface GnRHR cannot be explained with a conventional model assuming just 2
unliganded versus GnRH/buserelin occupied versus cetrorelix occupied) implies the ex
otion that GnRHR show ligand biased efﬁcacy and that the phenomenon is relevant to
urface GnRHR number but also to increase the number of GnRHR at the cell surface and it
ot yet observed any functional correlate of the more modest increase in cell surface Gn
rrows indicate whether the parameter is increased or decreased and “–” indicates that tr Endocrinology 331 (2011) 194–204
in hormone-dependent cancers) where coupling to effectors other
than Gq/11 may occur, and effects of agonists have been found to
be mimicked rather than blocked by peptide antagonists (Eidne et
al., 1987; Imai et al., 1997; Emons et al., 1998; Limonta et al., 2003;
Moretti et al., 2003; Maudsley et al., 2004).
6. GnRHR signalling TO ERK
Like many other 7TM receptors, GnRHR activate the extracellu-
lar signal-regulated kinase (ERK) cascade (Caunt et al., 2006a). In
many cellmodels ofGnRHsignalling, ERK controls the transcription
of both LH and FSH, which in turn regulate fertility. This appears to
reﬂect the in vivo scenario, as pituitary-speciﬁc removal of ERK1/2
in mice reduces LH synthesis and causes female infertility (Bliss
et al., 2009). Cellular context can also have a large inﬂuence on
mechanisms of ERK activation by GnRH. In gonadotroph-lineage
cells, ERK activation typically occurs through PKC-dependent acti-
vation of Raf (Liu et al., 2002), but in some cells of neuronal origin,
PKC-dependent transactivation of epidermal growth factor (EGF)
receptors provides the main route of ERK activation (Shah et al.,
2003a,b).Asnotedabove, oneof thepeculiar featuresof type Imam-
malian GnRHR is that they lack the C-terminal intracellular tails
required to mediate -arrestin binding and receptor desensitisa-
tion (Heding et al., 2000;McArdle et al., 2002; Ronacher et al., 2004;
Hislop et al., 2005; Caunt et al., 2006b). Non-mammalian GnRHR
can bind -arrestin and can signal to ERK in the cytoplasm via
arrestin-dependent routes, whilemammalian type I GnRHR appear
to utilise other scaffolds to control the kinetics and compartmen-
talisation of ERK signals (Caunt et al., 2006a,b). Recent studies in
gonadotrophs have described cytoplasmic signalling scaffolds that
are necessary for GnRH signalling to ERK in caveolin rich lipid rafts
(Navratil et al., 2003). Studies have additionally shown that paxillin
and Pyk2 can act as scaffoldswithin focal adhesions, which serve to
form a complex of ERK activating proteins and regulators (such as
PKC isoforms, c-Src and KSR-1) along with core components of the
ERK cascade (such as MEK and ERK) (Farshori et al., 2003; Dobkin-
Bekman et al., 2009). Experiments in HEK293 cells have also shown
that GnRH signals to ERK via a complex including focal adhesion
kinase and c-Src in the cytosol (Davidson et al., 2004a,b). Despite
their importance, the regulators that control ERK activity and local-
isation in the cell nucleus (as opposed to the cytosol) in response
to GnRH signalling remain relatively poorly studied.
Many ERK activating stimuli increase expression of nuclear-
inducible dual-speciﬁcity phosphatases (DUSPs) and GnRH has
beenshownto increaseexpressionofDUSP1and4 ingonadotrophs,
but their full effect on ERK signalling is unclear (Zhang et al.,
2001a,b; Davidson et al., 2004b). The potential complexity of this
system is illustrated by the fact that ERK is activated by a single
kinase (MEK), but can be inactivated by at least 13 phosphatases.
nterograde trafﬁcking Retrograde trafﬁcking Effect on PCSE
low Slow N/A
↑↑ ↓↓
↓ ↑
↑ – ↑↑
cribed in the text. In terms of cell surface receptor signalling via Gq/11, GnRH and
ptide antagonist IN3 increases anterograde trafﬁcking (of hGnRH, h.XGnRHR and
H, buserelin and cetrorelix) have little or no effect on this parameter. In contrast,
etrorelix can slow it and IN3 has little or no effect. These functional characteristics
GnRHR conformations (active and inactive). The three distinct functional proﬁles
istence of at least 3 conformations of cell surface GnRHR. These data support the
ligands used therapeutically. Note also that IN3 has the potential to increase cell
s overall effect on GnRH signalling reﬂects the balance of these two effects. We have
RHR expression caused by the peptide antagonist cetrorelix. N/A=non-applicable.
he measure is unchanged (as compared to the unliganded receptor).
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Fig. 3. Spatiotemporal characteristics of GnRH and PDBu-stimulated ERK regulation revealed using an ERK knock-down and add-back model. Cells were transfected in
96-well plates with ERK1/2 siRNAs and transduced with Ad ERK2-GFP and Ad mGnRHR prior to stimulation with 10−6 M GnRH or PDBu for the times indicated. They were
then ﬁxed and stained before image acquisition and analysis for the calculation of whole-cell ppERK2 intensity (upper left panel) and the N:C ERK2-GFP ratio (lower left
panel). Representative regions of cell images are also shown for DAPI, ERK2-GFP and ppERK2 in cells stimulated with 10−6 M GnRH or PDBu as indicated (right panels). Note
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dapted from Armstrong et al. (2009c).
ith this in mind we have developed HCM methods for explor-
ng how DUSPs may shape GnRH-mediated ERK signalling (Caunt
t al., 2008a,b; Armstrong et al., 2009c). This involves staining
ells in 96-well plates after treatment with antibodies to both
RK and dual-phosphorylated (pp) ERK and a DAPI stain for DNA.
utomated image acquisition and analysis then provides a high
hroughput method of comparing ERK and ppERK compartmental-
sation (Fig. 3). We have further developed a method for studying
RK function in which siRNAs (targeted to non-coding regions) are
sed to remove endogenous ERK1/2, and Ad are used to express
ither GFP-tagged wild-type ERK2, or a mutated allele of ERK2 to
robe function. This allows live cell studies of ERK trafﬁc or a coun-
erstain for ppERK in the same cells can be included. The removal
f endogenous ERK1/2 is important, ﬁrstly to allow staining for
pERKwithout interference fromendogenousERK1/2and secondly
ecause overexpression of ERK can swamp binding partners and
ask normal localisation changes. Using numerical ﬁlters, individ-
al cells expressing sub- or super-physiological levels of ERK2 can
e excluded from analysis to prevent bias of data towards a highly
nder or over-expressing subpopulation of cells. We used these
ethods to assess howMKPs and other DUSP familymembers con-ribute to the stimulus speciﬁcity of ERK responses to GnRH, EGF
r the PKC-activating phorbol ester, PDBu (phorbol 12, 13 dibu-
yrate). Using siRNA knock-down of DUSPs in a model HeLa cell
ine prior to stimulation with GnRH, EGF or PDBu for acute or sus-
ained periods,we found that 12 of 16 phosphatases tested affectedtention of ERK2-GFP are only seen at 120min in the PDBu stimulated cells (scale
either ERK localisation, compartmentalisation or phosphorylation
state (Caunt et al., 2008a). When each variable of stimulus, readout
or timingwas taken into consideration, therewas almost no redun-
dancy of effect of the individual DUSP siRNAs (Caunt et al., 2008a).
Speciﬁcally, we found that the nuclear family of MKPs (comprising
DUSP1, 2, 4 and 5) constitute negative regulators of ERK activity in
the nucleus in response to PKC activation, while the JNK/p38 fam-
ily MKPs (DUSP10 and 16) are positive regulators of ERK (Caunt et
al., 2008a). These ﬁndings were corroborated by using the “knock-
down, add-back” system to introduce a D319N mutated ERK2-GFP
construct, which abrogates binding to docking (D)-domain con-
taining proteins (including all MKPs), and mimicked the effects of
nuclear MKP knock down (Caunt et al., 2008a,b). While the major-
ity of GnRH signalling to ERK is mediated by PKC in this model, we
found ﬁrstly that GnRH-mediated ERK signalling kinetics were dis-
tinct from those mediated by PDBu, and that they were unaffected
by DUSP1 or 4 knock-down (Armstrong et al., 2009c). However,
we did ﬁnd that GnRH-induced ppERK signals were potentiated
either by D319N mutation of ERK or inhibition of protein synthesis,
which indicates that signal termination is (at least inpart)mediated
by high turnover, D-domain containing phosphatases (Armstrong
et al., 2009c). We additionally found that DUSP3, 5, 9, 10 and
16 were able to inﬂuence GnRH-mediated ERK phosphorylation
and/or localisation (Armstrong et al., 2009c). These data indicate
the need for further study into how the DUSPs regulate ERK activ-
ity in response to GnRH. They also highlight the fact that multiple
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ndpoint and condition experiments are crucial in deﬁning DUSP
unction in such systems.
. Decoding GnRH pulse frequency
Asnoted above,GnRH is secreted inbrief pulses. Pulse frequency
aries under different conditions (i.e. through the menstrual cycle)
nd GnRH effects on its target cells are frequency-dependent. This
as illustrated in early studies where constant GnRH suppressed
H and FSH secretion, whereas restoration of GnRH pulses restored
onadotropin secretion (Belchetz et al., 1978). Similarly, expression
f genes for rodent LH, FSH and the GnRHR are all increased
ore effectively at low or intermediate GnRH frequency (brief
ulses at 30–120min intervals) than at high frequency (pulses at
–30min intervals) or with sustained stimulation (Dalkin et al.,
989; Weiss et al., 1990; Shupnik, 1990; Haisenleder et al., 1991;
aiser et al., 1993; Yasin et al., 1995; Bedecarrats and Kaiser, 2003;
erris and Shupnik, 2006). Pulsatile agonists can be used to stimu-
ate gonadotropin secretion, whereas sustained agonist treatment
ltimately reduces gonadotropin secretion and this underlies ago-
ist efﬁcacy against steroid hormone-dependent cancers (Conn
nd Crowley, 1994; Schally, 1999). Given its physiological and
harmacological relevance, there is a great deal of interest in
he mechanisms underlying GnRH pulse frequency decoding and
nique featuresof these receptors (above)provideavaluablemodel
or exploring 7TM receptor mediated frequency decoding without
he complications of G-protein-independent signalling or receptor
esensitisation. Two of the major signalling pathways activated by
nRHR mediate frequency decoding in other systems. Thus, ERK-
ependent transcription is dependent upon stimulus frequency in
ome models (Cullen and Lockyer, 2002), and the fact that targeted
nock-down of ERKs causes infertility conﬁrms the importance of
his pathway in mediating responses to physiological (pulsatile)
timulation (Bliss et al., 2009). Similarly, GnRHR-mediated acti-
ation of the Ca2+/calmodulin pathway can affect gonadotropin
ubunit gene expression (Haisenleder et al., 2003a,b; Burger et
l., 2008) and calmodulins are well established as frequency-
ecoders in other systems (Hanson et al., 1994; De Koninck and
chulman, 1998;Craskeet al., 1999;Mermelstein et al., 2001).More
ecently, the NFAT, has been implicated in transcriptional regu-
ation by GnRH (Oosterom et al., 2005; Lim et al., 2007; Gardner
nd Pawson, 2009), speciﬁcally in repression of the FSH subunit
ene (Lim et al., 2007). NFATs are transcription factors activated by
a2+/calmodulin-dependent activation of the protein phosphatase
alcineurin (which dephosphorylates NFAT) and their possible role
n mediation of GnRH action is of particular interest in light of
he well established role of NFATs as frequency decoders in other
ystems (Li et al., 1998; Dolmetsch et al., 1998; Tomida et al.,
003; Berridge, 2006). There is also the potential for cross-talkwith
he non-canonical Wnt/Ca2+ pathway as GnRH mediates phospho-
nhibition of GSK3 which phosphorylates NFATs and thereby
pposes their transcriptional activity (Gardner et al., 2007).
The simplest frequency-dependent signalling scenario is one
n which a train of brief stimuli elicits a series of corresponding
esponses in a process known as digital tracking (Berridge, 2008).
owever, down-stream responses are typically activated and inac-
ivated more slowly than upstream signals so responses may
ot have returned to the pre-stimulation base-line before repeat
timulation. This can yield saw-tooth or cumulative responses
Krakauer et al., 2002; Ferris and Shupnik, 2006; Berridge, 2008)
n a process known as integrative tracking. This can provide
ignal speciﬁcity and amplify signalling but cannot explain the
ell-shaped frequency–response relationships often seenwith pul-
atile stimulation paradigms. These require positive or negative,
eed-back or feed-forward loops (Krakauer et al., 2002). The lackr Endocrinology 331 (2011) 194–204
of rapid homologous type I mammalian GnRHR desensitisation
excludes one potential feedbackmechanismbut agonists do stimu-
late GnRHR internalisation and thereby reduce cell surface GnRHR
number (Willars et al., 1999; Heding et al., 2000; Hislop et al.,
2005; Caunt et al., 2006b; Finch et al., 2009). Sustained GnRH also
down-regulates IP3 receptors (Willars et al., 2001; Wojcikiewicz et
al., 2003) and increases regulator of G-protein signalling-2 (RGS2)
expression, raising the possibility that this inhibits Gq/11 signalling
(Wurmbach et al., 2001; Karakoula et al., 2008). Similarly, GnRH
increases expression of DUSPs that could generate feedback loops
contributing to the frequency-decoding (Zhang et al., 2001a,b;
Zhang and Roberson, 2006; Armstrong et al., 2009c). Alternatively,
it has been proposed that frequency decoding at the LH pro-
moter involves Egr-1 and a co-regulator (Nab-2). In this model,
low GnRH frequency causes transient Egr-1 expression and conse-
quent expression ofNab-2which inhibits LH expression.Whereas
at high frequency there is a more sustained increase in Egr-1 and
this quenches Nab-2, increasing LH expression (Lawson et al.,
2007). Similar interplay between c-fos and the co-regulator TGIF
may also underlie preferential activation of the FSH promoter at
low GnRH pulse frequency (Tsutsumi and Webster, 2009). Alter-
natively, a recent study revealed that GnRH-induced expression of
ICER (inducible cAMP early repressor) antagonised the stimulatory
effect of CREB (cAMP reponse element binding protein) to specif-
ically inhibit FSH expression at high pulse frequency (Ciccone et
al., 2009).
A fundamental question raised by the data outlined above is
whether or not feedback effects shaping cytoplasmic signals are
actually relevant to GnRH frequency decoding. We have begun
to address this using an NFAT2-EFP live cell imaging reporter
(Armstrong et al., 2009b). We found that GnRH causes translo-
cation of NFAT2-EFP from the cytoplasm to the nucleus and
that this provides a robust readout for GnRHR-mediated acti-
vation of Ca2+/calmodulin/calcineurin/NFAT signalling. The effect
was reversible but was slower in onset and offset than the
underlying change in [Ca2+]i, and pulsatile GnRH caused dose-
and frequency-dependent NFAT2-EFP translocation (Fig. 3). At
low pulse frequency NFAT2-EFP translocation simply tracked
GnRHR occupancy but integrative tracking occurred at high fre-
quency (pulses every 30min), illustrating how relative dynamics
of upstream and downstream signals can increase efﬁciency of
cellular response to pulsatile GnRH (Fig. 3). We also used a pub-
lishedmathematicalmodel of GnRH signalling to predict responses
during pulsatile stimulation. This predicted desensitisation of
GnRHR-mediated effects on [Ca2+]i and that such desensitisa-
tion would increase with dose, pulse frequency and receptor
number (Armstrong et al., 2009b). However, no such desensiti-
sation was seen (using the NFAT2-EFP reporter) in HeLa or LT2
cells, possibly because pulsatile GnRH did not reduce cell surface
GnRHRexpression (Armstrong et al., 2009b). GnRHRactivation also
caused dose- and pulse frequency-dependent activation of GSU-,
LH- and FSH-luciferase reporters and each of these responses
was prevented by cyclosporin A, indicating dependence upon the
Ca2+/calmodulin/calcineurin pathway. Pulsatile GnRH also acti-
vated an NFAT-responsive luciferase reporter but its effect was
directly related to cumulative pulse duration. This, together with
the fact that we saw no desensitisation of the NFAT2-EFP translo-
cation responses argues that although NFATs may mediate GnRH
action, they are not genuine decoders of GnRH pulse frequency.
We have also used a similar approach (ERK2-GFP imaging) to test
for possible feedback regulation of GnRH-mediated ERK responses
during pulsatile stimulation (Armstrong et al., 2009a). As expected,
GnRH caused translocation of ERK2-GFP from the cytoplasm to the
nucleus providing a robust, live-cell readout for GnRHR-mediated
Raf/MEK/ERK activation. The effect was reversible and pulsatile
GnRH caused dose- and frequency-dependent ERK2-GFP translo-
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Fig. 4. Live cell imaging with varied GnRH pulse frequency. Panel A: HeLa cells were transduced with Ad-mGnRHR and Ad-NFAT2-EFP and treated with 0 or 10−7 M GnRH
for 20min, washed with ice-cold PBS, ﬁxed with 4% PFA, permeabilised and stained with DAPI. The panel shows representative images of cells acquired in the DAPI (blue)
and EFP (green) image channels, with an example of the automated image segmentation used to deﬁne perimeters of nuclei and cells. Scale bar: 30m. Panel B: cells
transduced with Ad-mGnRHR, Ad-NLS-BFP and Ad-NFAT2-EFP were treated with 10−9 M GnRH for 5min at 30min intervals, hourly intervals, or every 2h, as indicated. All
the wells were subject to half hourly washes (grey rectangles) 5min after GnRH or control addition. Digital images were acquired from live cells and used to calculate the
nuclear:cytoplasmic (N:C) ratio which was normalised to the control value obtained at time 0 in each well. Note that integrative tracking (i.e. the saw-tooth response seen
when responses have not returned to control values before repeat stimulation) occurred at the highest pulse frequency. Panel C shows the response to 30min pulses of
10−9 M GnRH along with the response seen in cells receiving constant stimulation with 10−9 M GnRH throughout the 4h experiment (dotted line) and the underlying [Ca2+]i
estimated using an established mathematical model for GnRH signalling (Washington et al., 2004).
Adapted from Armstrong et al. (2009b).
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ation (Armstrong et al., 2009a). These responses were faster in
nset and offset than the GnRHR-mediated NFAT2-EFP translo-
ation responses and showed only digital tracking of GnRHR
ccupancy (Fig. 4). Importantly, we saw no evidence for desen-
itisation of GnRH effects on ERK2-GFP translocation under any
ondition tested (dose, frequency and receptor number varied).
oreover, GnRH caused a frequency-dependent activation of an
gr1-responsive luciferase reporter (used as readout for ERK acti-
ation) but the response was directly related to cumulative pulse
uration (Armstrong et al., 2009a).
The data outlined above suggest that frequency decod-
ng cannot be attributed to feedback effects shaping
a2+/calmodulin/calcineurin/NFAT or Raf/MEK/ERK signalling.
n obvious caveat is that much of the live cell imaging was
erformed in HeLa cells and with relatively short periods of
timulation (maximally 8h). However, it is important to recognise
hat genuine GnRH frequency decoding does occur under these
onditions (as evidenced by bell-shaped frequency–response rela-
ionships for GnRH effects on LH-luc and FSH-luc reporters in
his model) and that where examined, the data obtained with the
maging reporterswas very similar in HeLa and LT2 (gonadotroph
ineage) cells (Armstrong et al., 2009b). Since we have found no
vidence for genuine frequency decoding in these pathways, our
ata are consistent with two alternative possibilities, (a) that
requency decoding occurs within other upstream signalling path-
ays or (b) that frequency decoding occurs downstream of these
athways. The latter possibility is the cornerstone of models where
ifferential regulation of FSH and LH expression is attributed to
he interplay of transcription factors and co-regulatory proteins
Lawson et al., 2007; Ciccone et al., 2009; Tsutsumi and Webster,
009).
. Conclusions and future directions
GnRHR are structurally and functionally unique. Notably, they
ave undergone a relatively recent period of accelerated molec-
lar evolution in which the advent of mammals has coincided
ith the loss of C-terminal tails and associated functions includ-
ng rapid desensitisation, agonist-induced phosphorylation and
rrestin-mediated signalling. The discovery that type I mammalian
nRHR do not desensitise underlines the importance of cell sur-
ace GnRHR number in determining responsiveness to GnRH, just
s the discovery that most hGnRHR are intracellular, underlines
he importance of compartmentalisation in determining cell sur-
ace GnRHR number. However, relatively little is known about the
hysiological relevanceandmoleculardeterminantsofGnRHRtraf-
cking to or from the cell surface. For example, we do not know the
roportion of GnRHR at the cell surface in human gonadotrophs or
hether this varies through the menstrual cycle, through puberty
r at other developmental stages. Similarly, we know that a mem-
rane permeant antagonist can increase the proportion of hGnRHR
t the cell surface, and that addition of a XGnRHR C-tail to the
GnRHR has a similar effect; yet the sorting proteins detecting
hese differences in conformation or primary structure are largely
nknown. We also know that agonists cause internalisation and
own-regulation of cell surface type I mammalian GnRHR but
echanisms have so far been deﬁned largely in negative terms
independence from receptor phosphorylation, arrestin binding
nd dynamin activity). The means by which agonists target these
eceptors for internalisation remain unknown. The high through-
ut provided by automated cell imagingwill undoubtedly facilitate
ork on these issues and has already led to the surprising obser-
ation that cetrorelix, a compound that acts as a competitive
nRHR antagonist in many functional assays, is actually an inverse
ntagonist for GnRHR internalisation. Most importantly, this workr Endocrinology 331 (2011) 194–204
demonstrates theoccurrenceof ligandbiasedefﬁcacywithhGnRHR
and in gonadotroph lineage cells, supporting the notion that it may
prove to be physiologically and/or therapeutically relevant. Finally,
we have found that automated imaging of ﬂuorescent protein
reporters provides a powerful means of interrogating GnRHR sig-
nalling to the Raf/MEK/ERK and Ca2+/calmodulin/calcineurin/NFAT
cascades. This has facilitated live cell imaging of signalling during
pulsatile GnRH stimulation, an approach thatwe consider essential
in addressing the fundamental and long-standing question of how
cells decode GnRH pulse frequency. To date our work has revealed
how integrative tracking can increase the efﬁciency of target cell
responsiveness to GnRH but also that these cascades appear not to
decode frequency (at least in HeLa and LT2 cells). Again, we are
optimistic that HCM approaches will prove valuable in addressing
alternatives, including the possibility that frequency decoding is
an inherent feature of alternative upstream signals or an emergent
feature of the network of signals passing from the cytoplasm to the
transcriptome.
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